Shionogi & Co., Ltd. — Xocova (ensitrelvir) $SGIOY

for COVID-19 post-exposure prophylaxis

NDA

FDA approved Xocova (ensitrelvir) as the first oral option for post-exposure prophylaxis of COVID-19, expanding the preventive toolkit beyond vaccines and the high-risk-only monoclonal antibody pemivibart.